The FDAnews Webinar Training Pass program offers year-round, unrestricted access to any of the hundreds of webinars listed below. These training programs feature thought leadership and best practices from top consultants, expert speakers and current and former FDA officials. New webinars are offered every month, along with access to the Webinar Training Pass archive.
BUY NOW Single-User 1-Year Unlimited Access $1,362
If you are already a Training Pass member, login below and then scroll down to view the list in date order or narrow your search by keyword or category. Viewing the webinar is easy… simply identify the webinar you want to watch, click on the title and the video will begin. If you would like to view or download the presentation materials separately from the video, click the "Download Presentation" link.
Also available: Take advantage of our multi-user and site licenses of the Webinar Training Pass, so you’ll have the most-informed workforce! Contact Russ Titsch, Business Development Director at russ.titsch@wcgclinical.com or +1 703.538.7651 to receive a custom quote.
Search by keyword, speaker name or just by category (drug, device or clinical) and you'll find all you need.
If you have any questions or are having any problems please give us a call on 703.538.7600 or email customer service.
Webinar Training Pass
Recorded on: Sept. 19, 2017
Description: Antitrust law expert August Horvath presents real-life scenarios that illustrate what you can and cannot say in advertising. He discusses:
- How misleading impressions occur, including why viewers misinterpret efficacy claims;
- How to list side effects to avoid misinterpretation;
- How to head off FDA or FTC actions against alleged unsubstantiated medical and comparison claims; and
- Proven techniques for substantiating claims.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: August T. Horvath, Antitrust Partner, Kelley Drye
Recorded on: Sept. 14, 2017
Description: FDA experts Wayne Pines, Jill Hartzler Warner and Dan Kracov discuss FDA Commissioner Scott Gottlieb’s first months in office, including:
- What the Gottlieb FDA is likely to continue and what will likely change;
- What unannounced priorities the commissioner may advocate in the future; and
- Gottlieb’s record and regulatory inclinations as well as unfolding events.
Presentation: Download the presentation
Transcript: Download the transcript
Speakers: Wayne Pines, President, Health Care APCO Worldwide; Jill Hartzler Warner, VP of Regulatory Policy, Catalyst Healthcare Consulting; and Dan Kracov, Partner, Arnold & Porter Kaye Scholer LLP
Recorded on: Sept. 13, 2017
Description: John Balzano, an expert on China’s medical device regulations, explains the current environment for devicemakers doing business in China, including:
- General reforms of China’s administrative system;
- Influence of reforms in other spaces; and
- Reform of the Chinese healthcare system.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: John Balzano, Special Counsel, Covington and Burling, LLP
Recorded on: Sept. 12, 2017
Description: Supplier accreditation experts Connie Conboy, Paul Hugo and Scott Goolsbey outline the benefits of using the MedAccred program to audit and certify suppliers. They cover:
- Meeting FDA requirements for purchasing controls;
- Verifying suppliers’ critical process capabilities;
- Evaluating suppliers’ equipment, personnel and controls; and
- How MedAccred audits differ from quality system audits.
Presentation: Download the presentation
Transcript: Download the transcript
Speakers: Connie Conboy, Director, Strategy & Business Development, Performance Review Institute; Paul Hugo, Director, Corporate Quality, Global Technologies; and Scott Goolsbey, Supplier Controls Manager, Stryker
Recorded on: Sept. 6, 2017
Description: Health economics and outcomes specialist Jeff Trotter explains the opportunities and pitfalls of using observational studies to show evidence of product safety and efficacy and discusses the impact of the 21st Century Cures Act. He covers:
- The critical link between strategy and operational efficiency in observational studies;
- Setting internal and external expectations for real-world evidence; and
- Best practices for ensuring clinical and commercial collaboration in support of observational studies and patient registries.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Jeff Trotter, President, Continuum Clinical
Recorded on: Aug. 31, 2017
Description: Regulatory expert Wayland Rushing explains the requirements of ICH guidance Q3D on elemental impurities in drug products. He covers:
- Comparison of ICH Q3D vs. USP requirements;
- Risk assessment and gathering information from suppliers;
- Analytical strategies and techniques; and
- Challenges associated with testing.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Wayland Rushing, Director of Scientific Affairs, EAG Labs
Recorded on: Aug. 24, 2017
Description: Quality systems expert Dan O’Leary analyzes the FDA’s two guidances on cybersecurity for medical devices. He covers:
- A design control framework for cybersecurity;
- The role of software verification and validation in cybersecurity;
- Identifying expected cybersecurity documents in the design history file; and
- Postmarket information, sources, and effect on cybersecurity.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Dan O’Leary, President, Ombu Enterprises, LLC
Recorded on: Aug. 22, 2017
Description: Biologics experts Suzanne Sensabaugh and Nitisha Pyndia explain the FDA’s view of interchangeability in biosimilars. They discuss:
- The most challenging areas of product development — including technical issues of similarity in purity and potency — and how to comply;
- How the FDA evaluates immunogenicity, a key factor entailing communication and cooperation with scientific colleagues;
- The chemistry of structural features; and
- Understanding the differences between interchangeability and biosimilarity.
Presentation: Download the presentation
Transcript: Download the transcript
Speakers: Suzanne M. Sensabaugh, President and Principal Consultant, and Nitisha Pyndiah, Consultant, HartmannWillner
Recorded on: Aug. 15, 2017
Description: Former director of the FDA Investigations Branch Ricki Chase explains FDA’s GMP guidance for combination products, focusing on the often-overlooked topic of design control. She discusses:
- How design controls apply to combination products, including biologic/device and drug/device combinations;
- How already available information can help speed new products to market; and
- Using human factor studies to support combination product submissions.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Ricki Chase, Director, Lachman Consultant Services, Inc.
Recorded on: Aug. 14, 2017
Description: FDA regulatory expert Jim O’Reilly discusses how the FDA plans to implement the variety of provisions in the 21st Century Cures Act and how those plans will affect manufacturers. He covers:
- How the FDA Science Board's new standards can lead to much faster product development approvals;
- How the FDA will allocate the $500 million authorized by Congress; and
- The role of the agency’s new Office of Translational Sciences, which governs the bench-to-clinical process.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Jim O’Reilly, Professor, University of Cincinnati College of Medicine